Vancouver, British Columbia, January 9, 2017 – Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSX VENTURE: APC) (Frankfurt: 0E8) is pleased to announce that it has filed intellectual property to cover methods for site-selective labeling of antibodies and related composition of matter that possess potential commercial value, particularly in the field of medicine and cancer therapies.

“2016 has been a transformational year for our Company as we have taken our core platform of site-selective labeling of proteins and transitioned to the fast growing antibody market,” said Dr. Allen Krantz, the Company’s CEO. “Since inception we have focused on developing technologies for site-specific labeling of proteins. However, during the course of the year, aspects of these technologies have been adapted to label antibodies, with the objective of attaching entities that improve their therapeutic and commercial properties, particularly with respect to antibody-drug conjugates (ADCs).”

“Given how difficult ADCs have been to produce in a pure and homogenous manner, they represent a compelling commercial target for site-selective labeling,” continued Dr. Allen Krantz. “Moving into 2017, APC’s goal will be to site-selectively attach entities such as drugs and toxins to antibodies using our linker technology to produce new and improved versions of antibody-drug conjugates (ADCs), but pursue an even more ambitious project, that of standardizing the process of constructing ADCs and producing a “one site fits all” solution.”

APC’s approach has been to design labeling entities that place a handle on the antibody selectively, to which a drug or toxin can be specifically attached. Conserved sites on antibodies, the type that all antibodies universally possess, are targeted by APC’s approach. Thus, in principle, the technology should ultimately enable the attachment of virtually any payload to any target antibody.

The intellectual property covered by these filings bears on activities being pursued in collaboration with the Toronto Recombinant Antibody Centre (TRAC) at the University of Toronto (UT), and Heidelberg Pharma GmbH, Ladenburg, Germany, a subsidiary of Wilex AG.

About APC

Advanced Proteome Therapeutics Corporation (APC) is advancing a site-specific protein modification technology platform to enable the development of superior protein therapeutics. Using this technology, APC has generated numerous and diverse modifications of annexin proteins with superior binding and stability properties, which are amenable to further labeling and conjugation for use in therapeutic applications. APC is now vigorously applying its technologies to achieve the site-specific labeling of therapeutic antibodies and provide the next generation of antibody-drug conjugates.


Advanced Proteome Therapeutics Corporation
Alexander (Allen) Krantz
President and Chief Executive Officer
Tel: 617-638-0340

Advanced Proteome Therapeutics Corporation
Babak Pedram
Investor Relations
Virtus Advisory Group Inc.
Tel: 416-644-5081

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will”, “should”, “future”, “potential” or similar expressions or by a general discussion of the Company’s strategies, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.